Ruth Gonzalez is 56, self-employed, and pays for her own health insurance. Her plan doesn't cover weight-loss drugs. When she decided to try Zepbound last year, she cut her phone plan, dropped streaming subscriptions, stopped buying Starbucks, and limited grocery spending to afford the roughly $350-a-month cost.
Within six weeks, her blood pressure had normalized. She lost more than 40 pounds. Her subsequent diagnoses of sleep apnea and incipient fatty liver disease — both weight-related — improved.
Then, in December 2025, Eli Lilly cut Zepbound's price by $50 to $100 per month. Gonzalez could afford a more effective dose. Now she's watching for a GLP-1 pill — expected to cost even less — that Lilly is developing.
Her story is becoming less unusual. The drugs are getting cheaper. The question is why — and whether it lasts.
The Numbers: How Far Prices Have Fallen
The GLP-1 class of weight-loss drugs launched at prices that made them inaccessible to most Americans without insurance coverage:
- Wegovy (semaglutide, Novo Nordisk) — launched in the US in June 2021 at a list price of more than $1,600 per month. As of early 2026, self-pay patients can access it for $149 per month through Novo Nordisk's direct program — a reduction of more than 90% from launch list price.
- Zepbound (tirzepatide, Eli Lilly) — launched in the US in late 2023 at a list price of more than $1,000 per month. Starting dose vials are now available to self-pay patients for $299 per month. Lilly cut prices by $50–$100 in December 2025.
- Both companies expect prices to continue falling as competition intensifies, patents approach expiry, and oral (pill-form) alternatives enter the market.
These are not insurance rebates or manufacturer coupons. They are published list prices for direct-to-consumer purchases — a model that has historically been rare in pharmaceutical markets, where pricing is normally negotiated in confidential contracts between manufacturers, pharmacy benefit managers (PBMs), insurance plans, and employers.
What GLP-1 Drugs Are and Why They're Different
GLP-1 stands for glucagon-like peptide-1 — a hormone naturally produced in the gut that regulates appetite and insulin secretion. GLP-1 receptor agonists mimic this hormone, producing two effects: they slow gastric emptying (you feel full longer) and suppress appetite signals to the brain (you feel less hungry).
The drugs were originally developed and approved for Type 2 diabetes management. Ozempic (semaglutide) and Mounjaro (tirzepatide) are the diabetes versions of Wegovy and Zepbound respectively — the same or similar compounds at different doses, approved for different indications. The weight-loss versions (Wegovy and Zepbound) required separate clinical trial programs and FDA approval specifically for obesity.
What made GLP-1s a cultural phenomenon was the scale of the effect. Clinical trials showed:
- Wegovy: average weight loss of approximately 15% of body weight over 68 weeks (STEP 1 trial, NEJM 2021)
- Zepbound (tirzepatide): average weight loss of approximately 20.9% of body weight over 72 weeks at highest dose (SURMOUNT-1 trial, NEJM 2022)
These results were unprecedented for pharmaceutical weight loss treatment, which had historically produced modest effects (3–7% body weight reduction) with significant side effect profiles. GLP-1s don't require surgery, have a manageable side effect profile (primarily nausea, especially in early weeks), and produce outcomes previously associated only with bariatric surgery.
The market is correspondingly enormous. The CDC estimates approximately 100 million American adults qualify as obese (BMI ≥ 30). A drug that demonstrably reduces weight by 15–21% for this population represents a potential market that analysts have variously estimated at $100–$150 billion annually in the US alone.
Why Prices Are Falling Here, and Not Elsewhere
The GLP-1 price war is a specifically American phenomenon — and it's driven by a structural peculiarity of the US drug market.
In most of the world, drug prices are set through negotiations between pharmaceutical companies and national health systems. The UK's NHS pays approximately £122 (roughly $155) per month for Wegovy through its national program. France, Germany, and Japan have similar negotiated rates well below US list prices. These prices are low because governments negotiate from a position of monopsony — they are the buyer for an entire country, and they can say no.
In the US, the federal government historically did not negotiate drug prices at scale. Medicare — which covers approximately 67 million Americans over 65 or with disabilities — was explicitly prohibited from negotiating drug prices under the 2003 Medicare Modernization Act, a provision that remained largely intact until the Inflation Reduction Act of 2022 began a limited negotiation program for a small number of high-cost drugs.
For most drugs, US pricing is set through a labyrinthine system of list prices, secret rebates, and confidential contracts negotiated by pharmacy benefit managers (PBMs) — private intermediaries who sit between drug manufacturers, insurance plans, and pharmacies. The actual price a patient pays depends on which PBM manages their plan, which drugs are on the plan's formulary, and what tier those drugs occupy.
GLP-1s broke this system open — not by design, but by accident.
Most private insurers and government programs declined to cover GLP-1s for weight loss. Medicare is explicitly prohibited from covering weight-loss drugs. Medicaid coverage varies by state but is limited. The calculation was financial: covering a $1,600/month drug for potentially millions of obese patients would cost insurers billions.
This left a massive population of patients willing to pay out of pocket — but only if prices were accessible. The pharmaceutical companies faced an unusual situation: they had a product with enormous consumer demand, no insurance intermediaries willing to route customers to them, and price-sensitive cash-pay customers shopping openly. For the first time in the modern US pharmaceutical market, there was an incentive to compete on published price.
The Direct-to-Consumer Model and What It Reveals
Novo Nordisk and Eli Lilly have both launched direct sales platforms. They've struck distribution deals with Walmart and Costco. They've fought court battles against compounding pharmacies selling off-brand semaglutide at lower prices during a supply shortage. And they've progressively cut prices to capture cash-pay market share from each other.
Trump's White House has also entered the space. In February 2026, the administration launched TrumpRx — a website routing customers directly to drug manufacturers for a select group of medications. The administration framed it as cutting out PBM "middlemen" and bringing transparency to drug pricing. Drugmakers, who have long blamed PBMs for obscuring the actual cost structure of drugs, were broadly supportive.
The USC economist's observation about transparency cuts to the core of what the GLP-1 situation reveals: when drugs are priced for direct consumer purchase, the entire negotiated-rebate architecture that normally obscures true drug costs becomes irrelevant. The list price is the price. Consumers can compare. Companies compete.
This is how most consumer markets work. It is not how most US prescription drug markets work.
The question for policy makers — and the reason this story matters beyond its immediate subject — is whether the competitive dynamics that drove GLP-1 prices from $1,600 to $149 can be replicated for other drug classes. The answer, most economists and health policy experts say, is: probably not easily. GLP-1s are unusual because:
- Demand is so large that manufacturers have strong incentives to capture marginal cash-pay patients
- Two well-capitalized competitors with similar products exist simultaneously, creating genuine price pressure
- Insurers opted out at scale, forcing the market to be direct
- The drugs are new enough that patent expiry and generic entry haven't yet commoditized the market, but close enough that manufacturers are racing to build customer loyalty before it happens
For most prescription drugs — where one manufacturer holds a patent, insurers do cover the product, and there's no direct competitor — none of these conditions apply. The GLP-1 price war is a special case. But it is a window into what drug competition can look like.
The Coverage Gap: Who Still Can't Afford It
Even at $149 to $299 per month, GLP-1s remain out of reach for a significant portion of the population that would benefit most from them. Key structural gaps:
Medicare: Federal law explicitly prohibits Medicare from covering anti-obesity medications. The Medicare Modernization Act of 2003 excluded weight-loss drugs from covered benefits. Approximately 18–20% of Medicare beneficiaries are classified as obese. Legislation to add GLP-1 coverage (the Treat and Reduce Obesity Act) has been introduced in multiple congressional sessions but has not passed.
Medicaid: Coverage varies by state. As of 2025, approximately 28 states cover at least one GLP-1 for obesity. The remaining states do not. Medicaid enrollees are disproportionately low-income — the population with the highest obesity rates and the least ability to pay out of pocket.
Private insurance: Approximately 75–80% of large employers cover GLP-1s as of 2025, according to the Business Group on Health — but with high cost-sharing, prior authorization requirements, and step therapy mandates (requiring patients to try and fail cheaper alternatives first) that limit practical access.
The result is a tiered market: patients with comprehensive employer-sponsored coverage pay modest copays; cash-pay patients face $150–$300/month; Medicare patients cannot access the drug for weight loss at any price through their federal coverage.
What Comes Next
Three developments will shape GLP-1 pricing over the next two to five years:
Oral formulations: Both Novo Nordisk (oral semaglutide) and Eli Lilly are developing pill-form GLP-1s. Pills are cheaper to manufacture, easier to distribute, and easier for patients to take than weekly injections. Their arrival is expected to compress prices further and expand the addressable market.
Patent expiry and generics: Semaglutide's core patents begin expiring in the late 2020s to early 2030s depending on jurisdiction. Generic manufacturers are already filing challenges. When generics enter, the price floor drops sharply — as it did with statins (cholesterol drugs) and metformin (a diabetes drug now available for pennies per dose).
Medicare coverage legislation: The political will to extend Medicare coverage for GLP-1s has grown with their clinical profile — particularly as data emerges showing GLP-1s reduce cardiovascular events (the SELECT trial, published 2023, showed a 20% reduction in major cardiovascular events in obese patients without diabetes). The cost argument against coverage weakens if the drug reduces downstream heart disease, hospitalization, and dialysis costs. CMS actuaries are actively modeling this tradeoff.
The drug that cost $1,600 a month in 2021 and $149 today is the same molecule. What changed wasn't the science — it was the market. And the market changed because, for once in the US pharmaceutical system, two well-funded companies ended up competing for customers who were paying their own money. That's worth understanding.